A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic presents significant global health challenges with limited therapeutic interventions.
• Existing treatments for COVID-19 often focus on symptom management and reducing inflammatory responses.

Purpose of the Study:

• To evaluate the efficacy of icosapent ethyl as an early anti-inflammatory treatment for symptomatic COVID-19 outpatients.
• To assess the impact of icosapent ethyl on high-sensitivity C-reactive protein (hs-CRP) levels and overall symptomatology.

Main Methods:

• A randomized open-label trial involving 100 ambulatory patients with symptomatic COVID-19 in Toronto, Canada.
• Patients received either icosapent ethyl (loading dose followed by maintenance dose) or usual care.
• High-sensitivity C-reactive protein (hs-CRP) levels and patient-reported symptoms were primary outcome measures.

Main Results:

• Icosapent ethyl treatment led to a significant 25% reduction in hs-CRP levels compared to usual care.
• Patients receiving icosapent ethyl reported improved symptomatology.
• The treatment regimen, including a loading dose, was well-tolerated by participants.

Conclusions:

• Icosapent ethyl demonstrates an early anti-inflammatory effect in symptomatic COVID-19 outpatients.
• This study provides preliminary evidence for icosapent ethyl as a potential therapeutic agent to manage COVID-19.
• Further research is warranted to confirm these findings in larger patient cohorts.